Medical Condition

ovarian cancer

Total Trials

54

Recruiting Now

54

Trial Phases

Phase 1, Phase 1, Phase 2, Phase 2

Ovarian cancer trials are shaped by the central role of BRCA1/2 mutation status and homologous recombination deficiency (HRD) in predicting response to PARP inhibitors — now standard maintenance therapy after first-line platinum-based chemotherapy for BRCA-mutated and HRD-positive disease. Despite PARP inhibitor approvals, platinum-resistant and BRCA wild-type advanced ovarian cancer remains a major unmet need driving frontline clinical research.

Active research includes next-generation PARP inhibitor combinations with anti-angiogenic agents and immune checkpoint inhibitors, mirvetuximab soravtansine (ADC targeting folate receptor alpha) in platinum-resistant disease, niraparib dose optimization, and VEGF/angiopoietin bispecific antibodies. Trials also evaluate intraperitoneal and heated intraperitoneal approaches for recurrent disease.

Most ovarian cancer trials require germline BRCA testing and often somatic tumor HRD testing; prior platinum therapy and number of prior lines determine eligibility for many studies.

Frequently Asked Questions — ovarian cancer Clinical Trials

How many clinical trials are currently recruiting for ovarian cancer?

ClinicalMetric currently tracks 54 actively recruiting clinical trials for ovarian cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 54. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for ovarian cancer?

ovarian cancer research spans Phase 1 (16 trials), Phase 2 (12 trials), Phase 3 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a ovarian cancer clinical trial?

Eligibility criteria for ovarian cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

M.D. Anderson Cancer Center 3 trials

University Health Network, Toronto 2 trials

Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2 trials

National Cancer Institute, Naples 2 trials

Memorial Sloan Kettering Cancer Center 1 trial

ovarian cancer

Frequently Asked Questions — ovarian cancer Clinical Trials

Recruiting Clinical Trials

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Trial of THEO-260 in Ovarian Cancer Patients

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

EXoPERT EMERALD Clinical Study

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Improved Diagnosis of Ovarian Cancer

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

Registry Platform Ovarian and Endometrial Cancer

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

The Better, Harder, Faster, Stronger Study

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

UNTOLD Ovarian Cancer Unmet Needs Survey

Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

Prospective Evaluation of the Role of MRI in Ovarian Masses During Pregnancy

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Shanghai Ovarian Cancer and Family Care Project

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients

Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

IDOV-Immune for Advanced Solid Tumors

Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

PPK Study Based on Quantitative Pharmacology in Patients With Pamipril

EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection

Feasibility of CALM in Patients With Ovarian Cancer

A Cohort Establishment Study of Total Management of Ovarian Cancer

PRO for Fighting FT in Ovarian Cancer

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

SLV-154 Treatment of Metastatic Solid Tumors

Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks